Samsung Biologics announced on the 25th that it has introduced two new Contract Development Organization (CDO) platforms at the ‘2024 Bio Process International (BPI)’ conference, a global bio…

The government has selected the ‘Korea Value Up’ Index as part of its efforts to address the Korea Discount, and 12 stocks from the healthcare sector have been included in the index. On the 24th,…

Lunit, a leading medical AI company focused on developing solutions that extend beyond diagnosis into treatment, is expected to see a steady increase in corporate value, according to industry…

Yuhan Corporation announced on the 11th that it will receive $60 million (approximately 80 billion KRW) in commercialization royalties for its non-small cell lung cancer treatment "lazertinib"…

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the Phase 2 clinical trial of "NLY01," a new drug candidate being developed by D&D…

Park Jaehyun, CEO of Hanmi Pharmaceutical, retained his position following a board decision that rejected the proposal to appoint Lim Jongyoon, an internal director, as CEO. On August 2, Hanmi…

SK Biopharmaceuticals has set an ambitious goal to emerge as a global player in the radiopharmaceutical(RPT) sector within the next three years. The company plans to strengthen its capabilities…

Celltrion has signed a listing agreement for Zymfentra with the major U.S. insurer Cigna, following its successful agreements with the three largest Pharmacy Benefit Managers (PBMs) just five months…

There is a growing consensus that aesthetic-focused companies, which demonstrated strong stock performance in Q2, will drive growth in the healthcare and medical device industries in the second half…

Voronoi, a drug development specialist that recently licensed out its autoimmune disease treatment pipeline to a U.S. pharmaceutical company, is expected to maintain its competitive edge in the…